Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the benzoylindole class, structurally related to indomethacin derivatives. It features an indole core substituted with a chlorobenzoyl group and additional methoxy and methyl groups, as well as an acetamide side chain with a chiral (R) hydroxymethylpropyl substituent. The compound is experimental and has been studied primarily in research settings. Its mechanism of action is presumed to involve inhibition of prostaglandin G/H synthase enzymes (COX enzymes), similar to other indomethacin analogs, but specific pharmacological data are limited. There are no known approved therapeutic indications or marketed products containing this molecule[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-n-[(1R)-1-(hydroxymethyl)propyl]acetamide.